Stocks

Record productivity gains from senior employees & AI, booming energy exports, and consumer spending is anticipated to boost GDP to a 5% annual pace in the second quarter.  As the Fed continues to cut key interest rates and the housing market improves, 6% annual GDP is even possible by the third quarter. Louis will reveal his best A-rated stock, many of which are data center-related.

AI is improving nearly every aspect of our lives. Stock investing is no different. But this presentation is for those who want to leverage the best that AI has to offer while not turning our backs on other sound fundamental investing principles.

In the presentation, Larry will discuss the charts in detail and go into his stock selection and risk management process.

Where are the best opportunities? What are the greatest risks? Our portfolio performance in 2025 was outstanding. Our silver stock pick (First Magestic Silver) more than tripled, performing far better than its more popular cousin, gold. Peru more than doubled and was a better play than just betting on copper (+32%). Clean energy was one of the top performers as well, with 60% gains compared to Nvidia’s 40%.

With oil and defense stocks and the S&P 500 at all-time highs, should you buy, hold, or sell? Will the safe havens continue to dominate returns? Are there any risks with Peru and copper? With Tesla, Microsoft, and Palantir down -21-31%, has the tide shifted toward value and away from growth?

Let’s dive into the data to design a blueprint that increases the performance and the protection of our portfolio.

Zhittya Genesis Medicine has developed a medicine to treat diseases caused by a lack of blood flow. During this presentation you will explore how Zhittya is using their FGF-1 to treat heart disease, Parkinson's disease, Type-2 Diabetes, and more.

Join David Keller, CMT for a powerful, interactive, and actionable fireside chat on markets in 2026. He will share his analysis of key market trends so far this year – including behind-the-scenes sector rotation, foreign market outperformance, volatility in precious metals, and more. He will also discuss what his technical indicators are showing and how investors and traders can best navigate volatile markets. Plus, he’ll explain what institutional investor-style tactics and strategies you can apply as an individual investor to maximize your portfolio returns.

CounterX Therapeutics is at the forefront of the battle against the opioid epidemic, exploiting cutting-edge biotechnology to develop life-saving therapeutics and vaccines. We combine scientific expertise with an experienced leadership team and a deep commitment to social impact. Our groundbreaking antibody therapies are designed to blunt the effects of opioids, reduce the risk of overdose, and provide a path to recovery. Additionally, our pioneering vaccine technology aims to prevent addiction relapse by blocking the euphoric effects of opioids and empowering individuals to maintain a long-term recovery.

The S&P 500 recorded a “three-peat” in 2025, or three successive years of double-digit gains. What is the likelihood of scoring a “four peat?” Even though CFRA thinks the bull will remain intact by year-end, it projects increased volatility along with a lower-than-average full-year percentage increase. Why so cautious? Still-high valuations, an elevated Buffett Indicator, a softening jobs market, late-cycle and defensive sector leadership, combined with mid-term elections that typically present formidable headwinds. Offsetting tailwinds include the fourth year of this bull market and double-digit earnings growth expectations, not only for 2026 but also for 2027. Sam Stovall, CFRA’s Chief Investment Strategist, will discuss what the market’s recent rotation implies for investor returns in the year ahead.